Search

Your search keyword '"Qiao, Guaiping"' showing total 3 results
Start Over Author "Qiao, Guaiping" Topic pharmacology
3 results on '"Qiao, Guaiping"'

1. Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia

Author

Wenqiang Cao, Li Han, Zhao Qianqian, Lei Tian, Xiaodong Ren, Yuling Ma, Hui Nan, Liu Yuzhi, Qiao Guaiping, Li Juan, Liang Chengyuan, and Hong Liu

Subjects
medicine.drug_class, Cellular differentiation, Retinoic acid, Antineoplastic Agents, Tretinoin, 01 natural sciences, 03 medical and health sciences, chemistry.chemical_compound, Leukemia, Promyelocytic, Acute, Drug Discovery, medicine, Humans, Retinoid, Receptor, neoplasms, PI3K/AKT/mTOR pathway, 030304 developmental biology, Cell Proliferation, Pharmacology, 0303 health sciences, 010405 organic chemistry, Chemistry, organic chemicals, TOR Serine-Threonine Kinases, Organic Chemistry, Autophagy, Cancer, General Medicine, medicine.disease, biological factors, 0104 chemical sciences, Cancer research, Acute promyelocytic leukaemia
Abstract

All-trans-retinoic acid (ATRA) is effective for preventing cancer and treating skin diseases and acute promyelocytic leukaemia (APL). These pharmacological effects of ATRA are mainly mediated by retinoid X receptors (RXRs) and retinoic acid receptors (RARs). This article provides a comprehensive overview of the clinical progress on and the molecular mechanisms of ATRA in the treatment of APL. ATRA can promote the transcriptional activation of differentiation-related genes and regulate autophagy by inhibiting mTOR, which results in anti-APL effects. In detail, the structures, pharmacological effects, and clinical studies of 68 types of ATRA analogues are described. These compounds have excellent antitumour therapeutic potential and could be used as lead compounds for further development and research.

Published
2020

2. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic

Author

Hui Nan, Xiaodong Ren, Pengcheng Yu, Hong Liu, Qiao Guaiping, Wenqiang Cao, Liu Yuzhi, Ju Xingke, Li Han, Jia Minyi, Lei Tian, Li Juan, and Liang Chengyuan

Subjects
Vero E6, African Green Monkey Kidney Epithelial-6, Huh-7, Human Hepatocellular Carcinoma-7, 3CLpro, 3C-like protease, HPLC, High-performance liquid chromatography, MOI, Multiplicity of infection, MERS, Middle east respiratory syndrome, AECOPD, Acute exacerbation of chronic obstructive pulmonary disease, Pharmacology, Other systems of medicine, IP-10, Interferon-inducible protein-10, Medicine, CCL-2/MCP-1, C-C motif ligand 2/monocyte chemoattractant protein-1, gp-130, Glycoprotein 130, HSV-1, Herpes simplex virus type 1, General Pharmacology, Toxicology and Pharmaceutics, qPCR, Quantitative PCR, media_common, MTT, Methyl Thiazolyl Tetrazolium, ERK, Extracellular signal-regulated kinase, CC50, 50% Cytotoxic concentration, IAV, Influenza A virus, HIV, Human immunodeficiency virus, mIL-6R, Membrane-bound form IL-6 Receptor, RSV, Respiratory syncytial virus, IL-8, Interleukin-8, Drug, media_common.quotation_subject, TCID50, 50% Tissue culture infective dose, COPD, Chronic obstructive pulmonary disease, Pharmacy, Article, DMSO, Dimethyl sulfoxide, mTOR, Mammalian target of rapamycin, HVJ, Hemagglutinating virus of Japan, medicine.disease, IBV, Influenza B virus, Clinical trial, CSS, Cytokine storm syndrome, Complementary and alternative medicine, RZ201-999, MIP-1β, Macrophage Inflammatory Protein-1β, IL-6R, IL-6 Receptor, MAPK, Mitogen-activated protein kinase, MOF, Multifunctional organ damage, AQP3, Aquaporins 3, PKA/p-CREB, Protein kinase A /phosphorylated cAMP response element-binding protein, nsps, Non-structural proteins, CXCL-10/IP-10, C-X-C Motif Chemokine Ligand 10/ Interferon Gamma-induced Protein 10, IFN-λ1, Interferon-λ1, Pandemic, PKB, Akt, Protein kinase B, ORFs, Open reading frames, CAT, COPD assessment test, COVID-19, Coronavirus disease 2019, Grb2, Growth factor receptor-bound protein 2, biology, LD50, 50% Lethal dose, TD50, Half-toxic dose, Cytokine storm syndrome (CSS), MLD50, 50% Minimum lethal dose, Hep-2, Human epithelial type 2, FBS, Fatal bovine serum, LH capsules, Forsythia honeysuckle (Lianhuaqingwen) capsules, CT, Computed tomography, NF-kB, Nuclear transcription factor kappa-B, M protein, Membrane protein, RT-PCR, Reverse transcription PCR, PLpro, Papain-like proteases, PI3K, Phosphoinositide 3-kinases, MDCK, Madin-darby canine kidney, Coronavirus disease 2019 (COVID-19), MCP-1, Monocyte chemotactic protein 1, PBS, Phosphate buffered saline, E protein, Envelope protein, RANTES, Regulated on activation normal T cell expressed and secreted, CPE, Cytopathic effect, PRC, People's Republic of China, Forsythia, MEK, Mitogen-activated protein kinase kinase, ACE2, Angiotensin-converting enzyme 2, ARDS, Acute respiratory distress syndrome, PHN, Phillyrin, IL-6, Interleukin-6, AIDS, Acquired immune deficiency syndrome, JAK/STAT, Janus kinase/signal transducers and activators of transcription, IC50, 50% Inhibition concentration, QC, Quality control, SARS-CoV-2, business.industry, Lianhuaqingwen, COVID-19, Forsythia honeysuckle (Lianhuaqingwen,LH) capsules, biology.organism_classification, CFDA, China Food and Drug Administration, JAK1/2, Janus kinase1/2, 3C-like protease (3CLpro), Ras, Ras GTPase, business, Cytokine storm, NHC, National Health Commission, TD0, Non-toxic Dose
Abstract

Highlights • The present review summarizes the plausible molecular mechanism of specific LH capsules in the control of SARS-COV-2 infection and the inhibition of cytokine storms caused by IL-6. • Preclinical and clinical trials of LH capsules in COVID-19 conducted in and outside China are elaborated. • A promising antiviral mechanism of LH capsules is defined, and the mechanism involving the suppression of inflammatory cytokine storms is explained. • Active substances in LH capsules that dock in ACE2 to prevent S protein binding are highlighted., Background In December 2019, a novel coronavirus, SARS-CoV-2 caused a series of acute atypical respiratory diseases worldwide. However, there is still a lack of drugs with clear curative effects, and the clinical trial research of vaccines has not been completely finished. Purpose LH capsules are approved TCM patent medicine that are widely used for the treatment of respiratory tract infectious diseases caused by colds and flu. On April 12, 2020, LH capsules and granules were officially repurposed by the China Food and Drug Administration (CFDA) for patients with mild COVID-19 based on their safety and efficacy demonstrated through multicentre, randomized, controlled clinical trials. We hope to conduct a comprehensive review of it through modern pharmacy methods, and try to explain its possible mechanism. Methods Using the full names of LH capsules Lianhuaqingwen, Lianhua Qingwen andSARS-COV-2, COVID-19 as the keywords of the search terms, systemically search for existing related papers in various databases such as Web of Science and PubMed. And completed the collection of clinical data in ClinicalTrials.gov and Chinese Clinical Trial Registry. Last but not least, we have sorted out the anti-inflammatory and antiviral mechanisms of LH capsules through literature and Selleck. Results This review systematically sorted out the active ingredients in LH capsules. Furthermore, the related pharmacological and clinical trials of LH capsule on SARS-CoV-2, IAV and IBV were discussed in detail. Moreover, the present review provides the first summary of the potential molecular mechanism of specific substances in LH capsules involved in resistance to SARS-COV-2 infection and the inhibition of cytokine storm syndrome (CSS) caused by IL-6. Conclusion This review summarizes the available reports and evidence that support the use of LH capsules as potential drug candidates for the prevention and treatment of COVID-19. However, TCM exerts its effects through multiple targets and multiple pathways, and LH capsules are not an exception. Therefore, the relevant mechanisms need to be further improved and experimentally verified., Graphical abstract Image, graphical abstract

Published
2021

3. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir

Author

Xie Xiaolin, Li Han, Lei Tian, Tang Yonghong, Zhang Dezhu, Zhenfeng Shi, Qiao Guaiping, Xu Zhao, Hui Nan, Liu Yuzhi, and Liang Chengyuan

Subjects
Drug, Emergency Use Authorization, Coronavirus disease 2019 (COVID-19), viruses, media_common.quotation_subject, Pneumonia, Viral, Review Article, Bioinformatics, medicine.disease_cause, Antiviral Agents, 01 natural sciences, Betacoronavirus, 03 medical and health sciences, Pharmacokinetics, Drug Discovery, Pandemic, medicine, Humans, Antiviral, Pandemics, 030304 developmental biology, media_common, Coronavirus, Pharmacology, Clinical Trials as Topic, 0303 health sciences, Alanine, SARS-CoV-2, 010405 organic chemistry, Chemistry, Organic Chemistry, COVID-19, General Medicine, Adenosine Monophosphate, COVID-19 Drug Treatment, 0104 chemical sciences, Clinical trial, RdRP inhibitor, Pharmacodynamics, Coronavirus Infections, Remdesivir (GS-5734)
Abstract

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed., Graphical abstract Image 1, Highlights • This article provides a comprehensive overview of remdesivir (GS-5734). • Remdesivir inhibits a variety of RNA viruses, including Coronaviridae, Filoviridae, Paramyxoviridae and Arenaviridae . • The remdesivir synthetic routes were comprehensively collected and are presented as a compilation of roadmaps. • The mechanism and clinical trial information of remdesivir for the treatment of COVID-19 are summarized.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results